Peptonic Medical AB (publ) successfully closes a SEK 5 million private placement
Stockholm, 17 December 2015. Peptonic Medical AB (publ) (“Peptonic Medical” or the “Company”) - a company developing pharmaceutical products based on oxytocin - today announced that it has completed a directed rights issue (private placement) in accordance with the authorisation of the Annual General Meeting. The issue was directed to Humle Kapitalförvaltning (“Humle”), which is not an existing shareholder of the Company, resulting in net proceeds of SEK 5,000,000 to the Company. Subscription price was SEK 3.05 per share, which corresponds to the price of the recently closed rights issue plus 0.25 SEK. The Board considers this to be a well-founded market price for a large investor.
In connection with the recently concluded rights issue, Humle expressed an interest in investing in the Company. Due to the high oversubscription, allotment of subscription rights to Humle was not possible. The Board considers the support and commitment of a large investor like Humle to be beneficial for the Company.
As a result of this private placement, the number of shares will increase by 1 639 344 to 19 174 385, corresponding to a share capital of 1,917,438.50 SEK.
”This additional capital injection means that we can complete the planned phase 2b study with the best possible support and be better prepared for the licensing activities before entering phase 3”, says Johan Inborr, CEO, and continues: ”We also welcome this opportunity to tie a shareholder with a long term view to the Company”.
_____
For more information, please contact:
Johan Inborr, CEO
Phone: +46 708 853 893
E-mail: johan.inborr@peptonicmedical.se
About Peptonic Medical AB (publ)
Peptonic Medical AB (publ) is an innovative Swedish pharmaceutical company developing oxytocin based products e.g. for the treatment of menopausal symptoms, such as vaginal atrophy. Oxytocin has a long history of safe medical use and offers an alternative to estrogen and estrogen-like acting compounds for menopausal and postmenopausal women. Peptonic Medical AB (publ)’s mission is to develop safe and effective drugs based on oxytocin.